Retrospective analysis of tegafur/uracil (UFT) plus oral leucovorin (LV) regimen in patients with advanced colorectal cancer

Yozo Sato, Yoshitaka Inaba, Hidekazu Yamaura, Hiroshi Shimamoto, Hideyuki Nishiofuku, Takashi Oyama, Yukihide Kanemitsu, Akira Sawaki, Yasuaki Arai, Kei Muro

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

The clinical efficacy and safety of tegafur/uracil (UFT) plus oral Leucovorin (LV) regimen for advanced or metastatic colorectal cancer were studied retrospectively. From September 2003 to March 2005, 82 patients were treated with UFT (300 mg/m(2)/day)/LV (75 mg/day) at our institute. The objective overall response rate was 14. 8% (95% confidence interval, 5.3 to 24.3%) in 54 evaluable patients. The response rate was 33.3% for previously untreated patients and 5.5% for previously treated patients, respectively. Grade 3 or more severe adverse reactions such as diarrhea or liver function abnormalities were only 7.3%. In 28 previously untreated patients,the median survival was 25.8 months with 1-and 2-year survival rates of 88.0% and 60.5%, respectively. This retrospective study demonstrated the reproducible activity and safety of UFT/LV for advanced or metastatic colorectal cancer in clinical practice.

Original languageEnglish
Pages (from-to)887-890
Number of pages4
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume33
Issue number7
Publication statusPublished - 07-2006
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Retrospective analysis of tegafur/uracil (UFT) plus oral leucovorin (LV) regimen in patients with advanced colorectal cancer'. Together they form a unique fingerprint.

Cite this